The present study was undertaken to develop and evaluate dispersible tablets of Cimetidine, a BCS Class III H₂-receptor antagonist, using different super disintegrants to improve tablet dispersion, patient compliance, and drug dissolution. Eight formulations (F1–F8) were prepared by the direct compression technique employing Crosspointe, Croscarmellose Sodium (CCS), and Starch at varying concentrations. The prepared powder blends exhibited satisfactory pre-compression properties with acceptable angle of repose, bulk density, tapped density, Carr's index, and Hausner's ratio, indicating good flow characteristics. All compressed tablets complied with pharmacopeial specifications for weight variation, hardness, thickness, friability (<1%), and drug content (98–102%). The disintegration time of the formulations ranged between 22–68 seconds, while wetting time varied from 18–55 seconds. In vitro dissolution studies revealed rapid drug release, with the optimized formulation achieving approximately 98–99% cumulative drug release within 30 minutes, demonstrating significantly enhanced dissolution compared with other formulations. The improved performance was primarily attributed to the efficient swelling and wicking action of the selected super disintegrants. Overall, the optimized dispersible tablet formulation exhibited excellent physicochemical characteristics, rapid dispersion, and superior dissolution behavior, indicating its potential as a patient-friendly oral dosage form for pediatric, geriatric, and dysphagic patients requiring immediate therapeutic action.